Condition
PR-Positive Breast Cancer
Total Trials
6
Recruiting
2
Active
2
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 100/100
Termination Rate
33.3%
2 terminated out of 6 trials
Success Rate
0.0%
-86.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
2 of 0 completed with results
Key Signals
2 with results0
Data Visualizations
Phase Distribution
6Total
Not Applicable (1)
P 1 (2)
P 2 (3)
Trial Status
Terminated2
Recruiting2
Withdrawn1
Not Yet Recruiting1
Clinical Trials (6)
Showing 6 of 6 trials
NCT04886531Phase 2Recruiting
Trial of Pre-operative Neratinib and Endocrine Therapy With Trastuzumab in ER-Positive, HER-2 Positive Breast Cancers
NCT07482384Not ApplicableNot Yet Recruiting
Supporting Health Including Endocrine Treatment for Long Duration
NCT04504331Phase 1Terminated
Study of Infigratinib in Combination With Tamoxifen in Hormone Receptor Positive, HER2 Negative, FGFR Altered Advanced Breast Cancer
NCT04504916Phase 2Terminated
A Study of Zilovertamab Vedotin (MK-2140/VLS-101) in Participants With Solid Tumors (MK-2140-002)
NCT05868226Phase 1Recruiting
PRE-I-SPY Phase I/Ib Oncology Platform Program
NCT04901299Phase 2Withdrawn
Fulvestrant + Neratinib In Breast Cancer
Showing all 6 trials